Answers are grounded in this paper and cite their sources.
Repeated onabotulinumtoxinA treatments significantly reduce CFL severity based on FWS and PROs. Adverse event profiles remain consistent with approved GL labeling.
No takes yet. Share an insight, caveat, or question.
Carruthers et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: